D. Rott et al., Effect on survival of acute myocardial infarction in Killip classes II or III patients undergoing invasive coronary procedures, AM J CARD, 88(6), 2001, pp. 618-623
Citations number
13
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
The purpose of the present study was to determine whether patients with acu
te myocardial infarction (AMI) in Killip class II or III are likely to bene
fit from catheterization and coronary revascularization performed within 30
days of AML The study population was drawn from 2 national surveys perform
ed during 1996 and 1998 in 26 coronary care units operating in Israel. Our
analysis included 3,113 patients with AMI who were divided into 2 groups ac
cording to their admission Killip class: 2,484 patients (80%) in Killip cla
ss I, of whom 1,408 (57%) underwent cardiac catheterization and 1,076 were
treated noninvasively; and 629 patients in Killip class II or III, of whom
314 (50%) underwent cardiac catheterization and 315 were managed conservati
vely. Patients in Killip class II or III who were treated invasively had lo
wer mortality rates than their counterparts who were treated noninvasively
at 30 days: 7.6% versus 15.6%, respectively (adjusted odds ratio [OR] 0.52,
95% confidence interval [CI] 0.28 to 0.92), and thereafter from 30 days to
6 months, 4.3% versus 13.6%, respectively (OR 0.34, 95% CI 0.16 to 0.68).
In Killip class I patients, an invasive versus noninvasive management was n
ot associated with a better outcome at 30 days: 1.6% versus 3.2%, respectiv
ely (OR 0.58, 95% CI 0.32 to 1.05), but with similar mortality rates at 30
days to 6 months, 1.9% versus 2.0%, respectively (OR 1.46, 95% CI 0.79 to 2
.74). Thus, the present study suggests that patients with AMI in Killip cla
ss II or III on admission may benefit from cardiac catheterization and reva
scularization performed within 30 days from admission, whereas patients wit
h AMI in Killip class I are less likely to benefit from this approach. (C)
2001 by Excerpta Medica, Inc.